Menu
Memory-like natural killer cells for cancer immunotherapy
Seminars in Hematology, Gang et al, November 2020
Read More
ARCHIVE
ARCHIVE
Wugen
Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies
Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019
Read MoreWugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion
ST. LOUIS, April 30, 2019 /PRNewswire/ -- Wugen Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Mark Lewis, Ph.D., as Vice President of Finance…
Read MoreWUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development
ST. LOUIS, March 26, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced the appointment of Ayman Kabakibi, Ph.D., as Vice President of Research and…
Read MoreWUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR
ST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings…
Read MoreWUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting
ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…
Read MoreWUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis
ST. LOUIS, Nov. 13, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…
Read MoreWUGEN Announces Presentations at American Society of Hematology Annual Meeting
ST. LOUIS, Nov. 1, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…
Read MoreAn “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
Leukemia, Cooper et al, February 2018
Read MoreCytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses
Biol Blood Marrow Transplant, Wagner et al, March 2017
Read More
Copyright © 2022 Wugen. All Rights Reserved.
a COGNEO design